Zhejiang Huahai Pharmaceutical Co Ltd
600521
Company Profile
Business description
Zhejiang Huahai Pharmaceutical Co Ltd is engaged in research and development, production, and sales of multi-dosage preparations, biological drugs, innovative drugs, and specialty APIs. The company’s products include irbesartan hydrochlorothiazide tablets, losartan potassium tablets, paroxetine hydrochloride tablets, sertraline hydrochloride tablets, linagliptin tablets, dabigatran etexilate capsules, pemetrexed disodium for injection, esomeprazole magnesium enteric-coated capsules, torsemide injection, and others.
Contact
Xunqiao
Zhejiang Province
Linhai317024
CHNT: +86 57685010288
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
8,797
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,813.10 | 55.80 | 0.64% |
| CAC 40 | 8,199.29 | 18.95 | -0.23% |
| DAX 40 | 24,616.22 | 142.83 | -0.58% |
| Dow JONES (US) | 50,786.01 | 80.77 | -0.16% |
| FTSE 100 | 10,373.20 | 5.15 | 0.05% |
| HKSE | 24,556.54 | 100.52 | -0.41% |
| NASDAQ | 25,929.66 | 220.23 | 0.86% |
| Nikkei 225 | 64,654.22 | 629.62 | 0.98% |
| NZX 50 Index | 13,095.64 | 57.40 | 0.44% |
| S&P 500 | 7,405.73 | 21.99 | 0.30% |
| S&P/ASX 200 | 8,592.70 | 59.20 | 0.69% |
| SSE Composite Index | 3,970.34 | 11.00 | 0.28% |